Paradigm Biopharmaceuticals Ltd has released a press release.
Quarterly Update and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- PARs European Patent Granted for Bone Marrow Edema Lesions
- Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
- Paradigms ACL Phase 2 Clinical Trial Success
- PAR Successfully Completes A$5.75m Placement
- First Participant Dosed in PARs Phase 2b OA Clinical Trial
Later from Paradigm Biopharmaceuticals
- Half Year Accounts
- Paradigm reports osteoarthritis pain reduced by 50%
- Paradigms phase 2 clinical data update
- Paradigm OA Phase 2b Clinical Trial over 80% Recruited
- PAR - 50% reduction in osteoarthritis pain maintained
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals